Skip to Content

Meta Analysis of Three Trials: FAST, SPOTLIGHT & GLOW Exploring the New Target Claudin 18.2 in Gastric Cancer

Presented at ASCO GI, Davi Said Gonçalves Celso, critically evaluates zolbetuximab’s efficacy through a meta-analysis of three key trials: FAST, SPOTLIGHT, and GLOW. This analysis, involving 1,349 patients, demonstrates zolbetuximab’s significant potential in reducing disease progression and mortality, particularly in patients lacking HER2 and PD-L1 CPS markers.

Davi Said Gonçalves Celso

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top